

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
CC	L-028-2018	2018	Scanmed LLC	Omaha, NE, United States	Exclusive	Worldwide	E-183-2016	Computer-aided Diagnosis Of Prostate Cancer In Multi-parametric MRI
	L-111-2006	2006	iCAD, Inc.	Nashua, NH, United States	Nonexclusive	US	E-111-2002	Software for CT Colonography Computer Aided Detection
	L-122-2017	2017	Koninklijke Philips N.V.	Eindhoven, , Netherlands	Exclusive	Worldwide	E-093-2005	Laparoscopic Ultrasound Transducer Trackable With Magnetics
	L-145-2019	2019	Globin Solutions, Inc.	Pittsburgh, PA, United States	Nonexclusive	Worldwide	E-254-2003	Treatment Of Cardiovascular Conditions Using Nitrite Therapy
	L-159-2010	2010	Asthmatx, Inc.	Sunnyvale, CA, United States	Nonexclusive	US	E-244-2000	Endoluminal Radiofrequency Cauterization System
	L-025-2017	2017	Tocris Bioscience	Bristol, , United Kingdom	Nonexclusive	Worldwide	E-116-2016	CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE
	L-030-2017	2017	ConverGene, LLC	Gaithersburg, MD, United States	Exclusive	Worldwide	E-004-2016	Substituted Bicyclic Heteroaryl Inhibitors Of Bromodomain-containing Protein BRD4
	L-055-2015	2015	Lysosomal Therapeutics, Inc.	Boston, MA, United States	Exclusive	Other	E-257-2010	Glucocerebrosidase Activators As A Treatment For Gaucher Disease
	L-057-2015	2015	Vtesse, Inc.	Gaithersburg, MD, United States	Exclusive	Worldwide	E-050-2012	Uses Of Cyclodextrin And Cyclodextrin In Combination With Vitamin E For The Treatment Of All Lysosomal Storage Diseases
	L-080-2015	2015	Promega Corporation	Madison, WI, United States	Nonexclusive	Worldwide	E-300-2012	A Coincidence Reporter Gene-system For High Throughput Screening
	L-105-2016	2016	Mycovia Pharmaceuticals Inc.	Durham, NC, United States	Exclusive	Worldwide	E-020-2016	Antifungal Compound Process
	L-116-2013	2013	Millipore Sigma	Billerica, MA, United States	Nonexclusive	Worldwide	E-326-2008	Small Molecule Activators Of Human Pyruvate Kinase
	L-134-2015	2015	Subrimed, Inc	Los Angeles, CA, United States	Exclusive	Worldwide	E-211-2010	Novel Compounds For Treatment Of Giardiasis
NCI	L-002-2016	2016	Kite Pharma, Inc.	San Mateo, CA, United States	Exclusive	Worldwide	E-266-2011	MAGE Family Of Cancer/testis (C/T) Antigen Presented By Multiple HLA Class I Alleles.
	L-004-2007	2007	Life Technologies Corporation	Carlsbad, CA, United States	Nonexclusive	Worldwide	E-230-2002	Catalytic Domains Of Beta (1,4)-Galactosyltransferase I Having Altered Donor And Acceptor Specificities Domains, That Promote In Vitro Protein Folding And Methods For Their Use
	L-008-2015	2015	xMD Diagnostics, LLC	Annapolis, MD, United States	Exclusive	Worldwide	E-113-2003	Direct Cell Target Analysis
	L-011-2006	2006	Dako Denmark A/S	Glostrup, , Denmark	Nonexclusive	Other	E-091-2002	Zap70 Protein Expression in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) and Likely Mantle Cell Lymphoma (MCL)...
	L-015-1984	1984	Abbott Laboratories, Inc.	Abbott Park, IL, United States	Nonexclusive	Worldwide	E-722-1984	ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) VIRAL ENVELOPE PRO- TEIN AND METHOD OF TESTING FOR AIDS
	L-017-1989	1989	Schering AG	Berlin, , Germany	Nonexclusive	US	E-555-1985	HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
	L-019-2013	2013	Australian Institute of Marine Science	Queensland, , Australia	Exclusive	Worldwide	E-191-2002	CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF.
	L-022-2017	2017	Etubics Corporation	Seattle, WA, United States	Exclusive	Worldwide	E-055-2011	The Development And Use Of Vaccines (Non-Yeast, Non-Poxvirus Based) For The Prevention And/or Therapy Of Human Cancer
	L-024-1997	1997	Signet Laboratories, Inc.	Dedham, MA, United States	Nonexclusive	Worldwide	E-057-1994	MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-025-2004	2004	Carolina Biological Supply Company	Burlington, NC, United States	Nonexclusive	Worldwide	E-186-1995	MUTANT AEQUOREA VICTORIA FLUORESCENT PROTEINS HAVING INCREASED CELLULAR FLUORESCENCE
	L-025-2007	2007	Tocris Bioscience	, , United Kingdom	Nonexclusive	Worldwide	E-050-2000	Geldanamycin Derivative And Method Of Treating Cancer Using Same
	L-026-2005	2005	MedImmune, Inc.	Gaithersburg, MD, United States	Exclusive	Worldwide	E-385-1986	RECOMBINANT PSEUDOMONAS EXOTOXINS: CONSTRUCTION OF AN ACTIVE IMMUNOTOXIN WITH LOW SIDE EFFECTS
	L-029-1993	1993	Genelabs	Redwood City, CA, United States	Nonexclusive	Worldwide	E-317-1984	SEROLOGICAL DETECTION OF ANTIBODIES TO HTLV-III IN SER PATIENTS WITH AIDS AND PRE-AIDS CONDITIONS
	L-032-2017	2017	Midissia Therapeutics	San Francisco, CA, United States	Exclusive	Worldwide	E-116-2003	Immunogenic Peptides And Peptide Derivatives For Prostate And Breast Cancer Treatment
	L-036-2012	2012	GlobelImmune, Inc.	Louisville, CO, United States	Exclusive	Worldwide	E-056-2011	The Development And Use Of A Recombinant Brachyury Saccharomyces Cerevisiae (yeast) Vaccine For The Prevention And/or Therapy Of Human Cancer
	L-047-2006	2006	Chembio Diagnostic Systems, Inc.	Hauppauge, NY, United States	Nonexclusive	Worldwide	E-317-1984	ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) VIRAL ENVELOPE PROTEIN AND METHOD OF TESTING FOR AIDS
	L-048-2015	2015	PDS Biotechnology Corporation	Lawrenceburg, IN, United States	Nonexclusive	Worldwide	E-520-2013	Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein
	L-051-2013	2013	Cell Signaling Technology, Inc.	Danvers, MA, United States	Nonexclusive	Worldwide	E-094-1994	JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS (JAK-3)
	L-051-2017	2017	Riptide Bioscience, Inc	Vallejo, CA, United States	Exclusive	Worldwide	E-242-2015	Peptides Having Anti-Inflammatory Properties
	L-052-2018	2018	MedGene Therapeutics, Inc.	Silver Spring, MD, United States	Exclusive	Worldwide	E-085-2013	Selection Of CD8+ PD-1+ Or CD8+ TIM-3+ Cells From Peripheral Blood Of Cancer Patients Enriches For Tumor-Reactive Cells That Can Be Used For Adoptive Transfer In The Treatment Of Cancer
	L-054-2010	2010	Research Corporation Technologies, Inc. (RCT)	Tucson, AZ, United States	Nonexclusive	Worldwide	E-003-2007	Engineered CH2 Domain Antibodies (nanoCbdies)
	L-057-2016	2016	Millipore Sigma	Billerica, MA, United States	Nonexclusive	Worldwide	E-050-2000	Geldanamycin Derivative And Method Of Treating Cancer Using Same
	L-063-2011	2011	Epitomics, Inc.	Burlingame, CA, United States	Nonexclusive	Worldwide	E-555-1985	HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
	L-064-2011	2011	Epitomics, Inc.	Burlingame, CA, United States	Nonexclusive	Worldwide	E-091-2002	Zap70 Protein Expression in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) and Likely Mantle Cell Lymphoma (MCL)...
	L-066-2009	2009	Becton, Dickinson and Company	Franklin Lakes, NJ, United States	Nonexclusive	Worldwide	E-062-1990	MOLECULAR CLONES OF HIV 1 AND USES THEREOF
	L-067-2012	2012	GlobelImmune, Inc.	Louisville, CO, United States	Exclusive	Worldwide	E-289-2011	The Ability Of Novel Yeast-MUC1 Constructs To Mature Human Dendritic Cells (DCs) And Activate Human T Cells
	L-068-2004	2004	Jennerex Biotherapeutics Inc.	San Francisco, CA, United States	Exclusive	Worldwide	E-181-1999	Combined Growth Factor-Deleted and Thymidine Kinase-Deleted Vaccinia Virus Vector
	L-071-1993	1993	Invitrogen Corporation	Rockville, MD, United States	Nonexclusive	US	E-009-1989	DNA ENCODING A GROWTH FACTOR SPECIFIC FOR EPITHELIAL CELLS (KGF)
	L-071-2019	2019	Atara Biotherapeutics Inc.	South San Francisco, CA, United States	Exclusive	Worldwide	E-079-2008	Human Monoclonal Antibody Against Mesothelin
	L-075-2016	2016	Lentigen Corporation	Gaithersburg, MD, United States	Exclusive	Worldwide	E-008-2014	Thymic Stromal Lymphopoietin Receptor (TSLPR) Chimeric Antigen Receptors

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-076-2010	2010	Scancell Ltd.	Nottingham, , United Kingdom	Nonexclusive	Worldwide	E-183-1996	IDENTIFICATION OF TRP-2 AS A NEW HUMAN TUMOR ANTIGEN RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES
	L-077-2015	2015	Kite Pharma, Inc.	San Mateo, CA, United States	Exclusive	Worldwide	E-495-2013	T Cell Receptor Targeting An HLA-A2 Restricted Epitope Of Human Papillomavirus-16 E6
	L-079-2008	2008	Theranostics Health, LLC	Rockville, MD, United States	Exclusive	Worldwide	E-261-1998	Methods and Devices for Isolation and Analysis of Cellular Protein Content
	L-082-1996	1996	ZeptoMetrix LLC	Buffalo, NY, United States	Nonexclusive	Worldwide	E-317-1984	SEROLOGICAL DETECTION OF ANTIBODIES TO HTLV-III IN SER PATIENTS WITH AIDS AND PRE-AIDS CONDITIONS
	L-084-2019	2019	Biopredic U.S., Inc.	Overland Park, KS, United States	Nonexclusive	Worldwide	E-200-2001	Agents that Bind To And Inhibit Human Cytochrome P450 2C19
	L-086-2011	2011	Miltenyi Biotec B.V. & Co. KG	Berlin, , Germany	Nonexclusive	Worldwide	E-097-2009	Chimeric Mouse/human Anti-human ROR1 MAb 2A2
	L-087-2000	2000	Alexis Biochemicals Corporation	San Diego, CA, United States	Nonexclusive	Worldwide	E-025-1998	FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS
	L-089-2007	2007	Theranostics Health, LLC	Rockville, MD, United States	Nonexclusive	US	E-261-1998	Methods and Devices for Isolation and Analysis of Cellular Protein Content
	L-089-2016	2016	H2bio	Shrewsbury, MA, United States	Exclusive	Worldwide	E-236-2012	A Single-domain Human Antibody, SD1, Elicits Potent Antitumor Activity By Targeting A Novel Epitope In Mesothelin Close To The Cancer Cell Surface
	L-091-2011	2011	Quest Diagnostics Inc.	San Juan Capistrano, CA, United States	Nonexclusive	Worldwide	E-317-1984	HUMAN IMMUNODEFICIENCY VIRUSES ASSOCIATED WITH AIDS, A DIAGNOSTIC METHOD FOR AIDS AND PRE-AIDS, A KIT THEREFOR
	L-092-2012	2012	Admune Therapeutics LLC	Danvers, MA, United States	Exclusive	Worldwide	E-254-2005	Optimization Of Expression Of Human Interleukin-15 (IL-15) And Improved DNA Vector Combinations Of IL-15 And IL-15 Receptor Alpha And Protein Combinations Of Same That Increase Cytokine Stability And Biological Function In Vivo And In Vitro
	L-093-2010	2010	BioLytical Laboratories, Corp	Richmond, , Canada	Nonexclusive	US	E-722-1984	ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) VIRAL ENVELOPE PRO- TEIN AND METHOD OF TESTING FOR AIDS
	L-094-2020	2020	Innovative Cellular Therapeutics	Rockville, MD, United States	Nonexclusive	Worldwide	E-170-2009	Methods Of Preparing Lymphocytes That Express Interleukin-12 And Their Use In The Treatment Of Cancer
	L-095-2012	2012	BioLegend, Inc.	San Diego, CA, United States	Nonexclusive	Worldwide	E-097-2009	Chimeric Mouse/human Anti-human ROR1 MAb 2A2
	L-095-2013	2013	Bavarian Nordic, Inc.	Mountain View, CA, United States	Exclusive	Worldwide	E-099-1996	AGONIST AND ANTAGONIST PEPTIDES OF CEA
	L-099-2020	2020	Kite Pharma, Inc.	San Mateo, CA, United States	Exclusive	Worldwide	E-282-2016	Methods For Pre-conditioning Patients For Cell Therapy
	L-100-2005	2005	InvivoGen	San Diego, CA, United States	Nonexclusive	Worldwide	E-050-2000	Geldanamycin Derivative And Method Of Treating Cancer Using Same
	L-101-2007	2007	Cambridge Antibody Technology Limited	Cambridge, , United Kingdom	Exclusive	Worldwide	E-163-1993	RECOMBINANT DISULFIDE-STABILIZED POLYPEPTIDE FRAGMENTS HAVING BINDING SPECIFICITY
	L-104-2020	2020	T-Cure Bioscience, Inc.	Sherman Oaks, CA, United States	Exclusive	Worldwide	E-153-2016	T-cell Receptor Targeting The Cancer/testis Antigen KK-LC-1
	L-105-2010	2010	IR2Dx	Moraga, CA, United States	Nonexclusive	Worldwide	E-157-1994	CDNA For Human And Pig Dihydropyrimidine Dehydrogenase
	L-107-2010	2010	Tioma Therapeutics	St. Louis, MO, United States	Exclusive	Worldwide	E-227-2006	Regulating Blood Pressure Through Targeting Thrombospondin-1 And CD47
	L-107-2015	2015	lovance Biotherapeutics. Inc.	San Carlos, CA, United States	Exclusive	Worldwide	E-275-2002	Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-108-2009	2009	Beckman Coulter Inc.	Fullerton, CA, United States	Nonexclusive	US	E-307-2002	A Rugged Sheathless CE-ESI-MS Interface for Sensitive Nano-Flow Operation
	L-108-2015	2015	Lion Biotechnologies, Inc.	New York, NY, United States	Exclusive	Worldwide	E-059-2013	Selection Of CD8+ PD-1+, 41BB+ TIM-3+ Or LAG-3+ Cells From Tumor-infiltrating Lymphocytes (TIL) Enriches For Tumor-reactive Cells That Can Be Adoptively Transferred For The Treatment Of Cancer
	L-108-2020	2020	ElevateBio	Cambridge, MA, United States	Exclusive	Worldwide	E-133-2016	Chimeric Antigen Receptor Targeting Human FLT3
	L-113-2006	2006	Santa Cruz Biotechnology, Inc.	Santa Cruz, CA, United States	Nonexclusive	Worldwide	E-057-1994	MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS
	L-113-2007	2007	Ventana Medical Systems, Inc.	Tucson, AZ, United States	Nonexclusive	Worldwide	E-555-1985	HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
	L-117-2017	2017	Aspyrian Therapeutics, Inc.	San Diego, CA, United States	Exclusive	Worldwide	E-231-2015	Near Infrared Photoimmunotherapy (NIR-PIT) Of Negative Regulatory Foxp3+ (CD4+CD25+) T-cells In Tumors As A Highly Effective Cancer Treatment
	L-121-2011	2011	Globelmmune, Inc.	Louisville, CO, United States	Exclusive	Worldwide	E-184-2009	Combination Immunotherapy Compositions And Methods
	L-124-2013	2013	JSK Therapeutics, Inc.	Gainesville, GA, United States	Exclusive	Worldwide	E-093-1996	O2-ARYL SUBSTITUTED DIAZENIUMDIOLATES
	L-126-2010	2010	Enzo Life Sciences, Inc	Farmingdale, NY, United States	Nonexclusive	Worldwide	E-142-1999	Anti-γ-H2A Antibody, Fusion Proteins Thereof And Method And Kit For Determining Double-Stranded Breaks
	L-126-2020	2020	Kite Pharma, Inc.	Santa Monica, CA, United States	Nonexclusive	Worldwide	E-183-2017	Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen Chimeric Antigen Receptors
	L-127-2011	2011	Bavarian Nordic, Inc.	Mountain View, CA, United States	Exclusive	Worldwide	E-099-1996	AGONIST AND ANTAGONIST PEPTIDES OF CEA
	L-127-2020	2020	Kite Pharma, Inc.	Santa Monica, CA, United States	Nonexclusive	Worldwide	E-183-2017	Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen Chimeric Antigen Receptors
	L-134-2016	2016	Ardeagen Corporation	Woodinville, WA, United States	Exclusive	Worldwide	E-039-2011	Chimeric Rabbit/human Anti-human ROR1 Monoclonal Antibodies With Relevance For Cancer Therapy And Diagnosis- [3 New Chimeric Rabbit/human Anti-ROR1 IgG1 (named R11, R12, And Y31)]
	L-136-2020	2020	Intima Bioscience Inc.	New York, NY, United States	Exclusive	Worldwide	E-171-2018	MODIFIED CELLS AND METHODS OF THERAPY
	L-141-2005	2005	PerkinElmer Life and Analytical Sciences, Inc.	Boston, MA, United States	Nonexclusive	Worldwide	E-317-1984	SEROLOGICAL DETECTION OF ANTIBODIES TO HTLV-III IN SER PATIENTS WITH AIDS AND PRE-AIDS CONDITIONS
	L-142-2006	2006	ImClone Systems, Inc.	New York, NY, United States	Exclusive	Worldwide	E-040-1993	MONOCLONAL ANTIBODIES AGAINST THE ALPHA PDGF RECEPTOR AND USES THEREOF
	L-146-1994	1994	BD Biosciences - BD PharMingen	San Diego, CA, United States	Nonexclusive	(blank)	E-234-1989	Production and Use of Human NM23 Protein and Antibodies Therefore
	L-148-2006	2006	Santa Cruz Biotechnology, Inc.	Santa Cruz, CA, United States	Nonexclusive	Worldwide	E-099-1989	TYPE A PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE
	L-148-2017	2017	Chimeron Bio Corporation	Audubon, PA, United States	Exclusive	Worldwide	E-264-2011	Novel Delivery Of Packaged RNA In Mammalian Cells
	L-148-2018	2018	BravoVax Co., Ltd.	Wuhan, , China	Exclusive	Foreign	E-103-2005	Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies
	L-149-2008	2008	Bavarian Nordic, Inc.	Mountain View, CA, United States	Exclusive	Worldwide	E-256-1998	A Recombinant Vector Expressing Multiple Costimulatory Molecules and Uses Thereof
	L-153-2010	2010	Arko Laboratories Ltd.	Jewell, IA, United States	Nonexclusive	Worldwide	E-311-2006	Compositions And Methods For Chitosan Enhanced Immune Response

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-158-2017	2017	Mokobio Life Science Group, Inc.	Charlestown, MA, United States	Co-Exclusive	US	E-176-2015	Identification Of Lnc-FANCI-2 As A Biomarker For Diagnosis And Therapy Of HPV Infections With A High-risk Of Progression
	L-160-2018	2018	Advanced Imaging Projects, LLC (AIP)	Lake Worth, FL, United States	Exclusive	Worldwide	E-170-2004	Second Generation Integrin Avb3 Antagonists For Use In Imaging And Therapy
	L-164-2013	2013	Aura Biosciences, Inc.	Cambridge, MA, United States	Exclusive	Worldwide	E-184-2016	Targeted Combination Therapy
	L-165-1999	1999	Trinity Biotech, Plc	Bray, , Ireland	Nonexclusive	Worldwide	K-446-1987	HUMAN IMMUNODEFICIENCY VIRUS SPECIFIC PROTEOLYTIC ENZYME AND A METHOD FOR ITS SYNTHESIS AND RENATURATION
	L-165-2018	2018	EXBIO Praha	, , Czech Republic	Nonexclusive	Worldwide	E-097-2009	Chimeric Mouse/human Anti-human ROR1 MAb 2A2
	L-169-2015	2015	Enanta Pharmaceuticals, Inc.	Watertown, MA, United States	Nonexclusive	US	E-308-1987	CLONE FOR HUMAN MULTIDRUG RESISTANCE GENE
	L-178-2005	2005	BioGemex Ltd.	Kyung-gi, , South Korea	Nonexclusive	Other	E-081-2004	AUTOANTIBODY DETECTION FOR CANCER DIAGNOSTICS
	L-183-1999	1999	Abbott Molecular Inc.	Des Plaines, IL, United States	Nonexclusive	Worldwide	E-555-1985	HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
	L-188-2016	2016	Heliome Biotech, Inc	New York, NY, United States	Exclusive	Worldwide	E-508-2013	Method For Inhibiting The Intestinal Farnesoid X Receptor To Decreases Obesity-Associated Non-Alcoholic Fatty Liver Disease (NAFLD)
	L-190-1998	1998	ViroGen Corp.	Watertown, MA, United States	Nonexclusive	US	E-172-1986	CLONING AND EXPRESSION OF HTLV-III DNA
	L-190-2019	2019	ZioPharm Oncology, Inc.	Charlestown, MA, United States	Exclusive	Worldwide	E-031-2020	Human T Cell Receptor Targeting HLA-A*11:01-restricted KRASG12D Mutation
	L-191-2015	2015	University of Arkansas	Fayetteville, AR, United States	Nonexclusive	Worldwide	E-192-2008	Optimization Of Expression Of Multimeric Proteins
	L-201-2020	2020	Navrogen Inc	Glen Mills, PA, United States	Nonexclusive	Worldwide	E-198-2012	Novel Mesothelin Domain Rabbit Monoclonal Antibodies
	L-203-1994	1994	BD Biosciences - BD PharMingen	San Diego, CA, United States	Nonexclusive	Worldwide	E-099-1989	TYPE A PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE
	L-203-2001	2001	Zymed Laboratories, Inc.	South San Francisco, CA, United States	Nonexclusive	Worldwide	E-137-1990	MONOCLONAL ANTIBODIES FOR HUMAN THYMIDYLATE SYNTHASE
	L-206-2000	2000	Aurora Biosciences Corporation	San Diego, CA, United States	Nonexclusive	Worldwide	E-555-1985	HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
	L-208-2013	2013	Aspyrian Therapeutics, Inc.	San Diego, CA, United States	Exclusive	Worldwide	E-205-2010	Photoimmunotherapy Enhanced Drug Therapy: Immediately Following Photoimmunotherapy The Delivery Of Therapeutic Drugs To The Treated Area S Markedly (~10 Fold) Increased Resulting In Increased Local Concentration Of Drug Without Systemic Side Effects
	L-210-2015	2015	GlobelImmune, Inc.	Louisville, CO, United States	Exclusive	Worldwide	E-520-2013	Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein
	L-218-2016	2016	Kite Pharma, Inc.	San Mateo, CA, United States	Exclusive	Worldwide	E-042-2014	Novel Anti-CD19 Chimeric Antigen Receptors
	L-222-2020	2020	Senti Biosciences, Inc.	South San Francisco, CA, United States	Exclusive	Worldwide	E-133-2016	Chimeric Antigen Receptor Targeting Human FLT3
	L-224-2015	2015	2seventy bio	Cambridge, MA, United States	Exclusive	Worldwide	E-040-2012	Chimeric Antigen Receptors Targeting B-cell Maturation Antigen
	L-226-1996	1996	NeoPharm, Inc.	Potomac, MD, United States	Exclusive	Worldwide	E-385-1986	RECOMBINANT PSEUDOMONAS EXOTOXINS: CONSTRUCTION OF AN ACTIVE IMMUNOTOXIN WITH LOW SIDE EFFECTS
	L-231-2015	2015	Thirsty Brook Bioscience, Inc.	Newton, MA, United States	Exclusive	Worldwide	E-040-2012	Chimeric Antigen Receptors Targeting B-cell Maturation Antigen

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-232-2014	2014	NanoString Technologies Inc.	Seattle, WA, United States	Nonexclusive	Worldwide	E-750-2013	Molecular Diagnosis Of Lymphoma Subtypes Using Formalin-fixed, Paraffin-embedded Biopsy Specimens
	L-234-2000	2000	XenoTech, LLC	Lenexa, KS, United States	Nonexclusive	Worldwide	E-150-1998	Agents That Bind to and Inhibit Human Cytochrome P450 2A6
	L-239-2019	2019	Cartesian Therapeutics, Inc.	Rockville, MD, United States	Nonexclusive	Worldwide	E-040-2012	Chimeric Antigen Receptors Targeting B-cell Maturation Antigen
	L-245-1994	1994	BBI-Biotech Research Laboratories, Inc.	Gaithersburg, MD, United States	Nonexclusive	Worldwide	E-471-1985	Cell Line ( 8E5 ) Producing AIDS Viral Antigens Without Producing Infectious Viral Particles.
	L-255-2019	2019	BioE Holdings Inc.	Wilmington, DE, United States	Exclusive	Worldwide	E-168-2011	Genotype-specific Vaccination Against BK Polyomavirus
	L-258-2020	2020	Tocris Bioscience	Bristol , , United Kingdom	Nonexclusive	Worldwide	E-046-2019	Non-aggregating Heptamethine Cyanine Fluorophores For In Vivo Imaging
	L-259-2016	2016	Kite Pharma, Inc.	San Mateo, CA, United States	Exclusive	Worldwide	E-088-2020	HLA Class-II Restricted DPB1*03:01 T-cell Receptors Against The KRASG12V Mutation”
	L-259-2017	2017	CRISPR Therapeutics AG	Cambridge, MA, United States	Nonexclusive	(blank)	E-042-2014	Novel Anti-CD19 Chimeric Antigen Receptors
	L-268-2016	2016	Kite Pharma, Inc.	San Mateo, CA, United States	Exclusive	Worldwide	E-234-2014	Methods For Producing Autologous T Cells Useful To Treat B Cell Malignancies And Other Cancers
	L-271-2001	2001	Millennium Pharmaceuticals, Inc.	Cambridge, MA, United States	Exclusive	Worldwide	E-116-2001	Formulation of Boronic Acid Compounds
	L-273-2014	2014	Novartis Vaccines & Diagnostics	Cambridge, MA, United States	Nonexclusive	Worldwide	E-317-1984	Nucleic Acids And Peptides Of Human Immunodeficiency Virus Type-1 (HIV-1).
	L-274-2018	2018	Cellular Biomedicine Group, Inc (CBMG)	Rockville, MD, United States	Nonexclusive	Worldwide	E-059-2013	Selection Of CD8+ PD-1+, 41BB+ TIM-3+ Or LAG-3+ Cells From Tumor-infiltrating Lymphocytes (TIL) Enriches For Tumor-reactive Cells That Can Be Adoptively Transferred For The Treatment Of Cancer
	L-276-2014	2014	NanoString Technologies Inc.	Seattle, WA, United States	Nonexclusive	Worldwide	E-108-2004	Custom Lymphoid Malignancy Diagnostic DNA Microarray - Oligo Probes And Lymphoma Survival Prediction Algorithm
	L-282-2014	2014	Beacon Biomedical, Inc.	Phoenix, AZ, United States	Exclusive	Worldwide	E-290-2000	Detection And Quantification of Cripto-1
	L-289-2014	2014	British Columbia Cancer Agency	Vancouver, BC, Canada	Nonexclusive	Worldwide	E-108-2004	Custom Lymphoid Malignancy Diagnostic DNA Microarray - Oligo Probes And Lymphoma Survival Prediction Algorithm
	L-304-2019	2019	Intellia Therapeutics, Inc.	Cambridge, MA, United States	Nonexclusive	Worldwide	E-067-2017	A Novel Method To Isolate The Paired Sequences Of Neoantigen-specific T Cell Receptors
	L-308-2017	2017	Rapa Therapeutics LLC	Silver Spring, MD, United States	Nonexclusive	(blank)	E-063-2003	Adoptive T Cell Therapy Using Rapamycin-Resistant, CD28 Co-Stimulated Th1/Th2 And Tc1/Tc2 Cells
	L-317-2017	2017	Lentigen Corporation	Gaithersburg, MD, United States	Nonexclusive	Worldwide	E-033-2013	Stabilized Single Human CD4 Domains And Fusion Proteins As Exceptionally Potent HIV-1 Entry Inhibitors
	L-325-2017	2017	Diagnostic BioSystems	Pleasanton, CA, United States	Nonexclusive	Worldwide	E-136-2012	High-affinity Mouse Monoclonal Antibodies To Glypican-3 For Liver Cancer Therapy And Diagnosis
	L-327-2017	2017	Diagnostic BioSystems	Pleasanton, CA, United States	Nonexclusive	Worldwide	E-198-2012	Novel Mesothelin Domain Rabbit Monoclonal Antibodies
	L-329-2017	2017	Abpro	Woburn, MA, United States	Exclusive	Worldwide	E-136-2012	High-affinity Mouse Monoclonal Antibodies To Glypican-3 For Liver Cancer Therapy And Diagnosis
	L-331-2017	2017	Istari Oncology Inc.	Morrisville, NC, United States	Exclusive	Worldwide	E-267-2014	Novel Robust Production Process Of High Purity Polio Virus And Polio Virus Variants (PVS-RIPO)
	L-356-2014	2014	Georgia Health Sciences University Research Institute, Inc.	Augusta, GA, United States	Exclusive	Worldwide	E-126-2001	Human Papilloma Virus Immunogenic Peptides
	L-745-1991	1991	BioMerieux, Inc.	Durham, NC, United States	Nonexclusive	Worldwide	E-317-1984	SEROLOGICAL DETECTION OF ANTIBODIES TO HTLV-III IN SER PATIENTS WITH AIDS AND PRE-AIDS CONDITIONS

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
NEI	L-007-2013	2013	North Carolina State University (NCSU)	Raleigh, NC, United States	Nonexclusive	Worldwide	E-241-1999	Ocular Therapeutic Agent Delivery Devices And Methods For Making And Using Such Devices
	L-230-2002	2002	Bausch & Lomb, Inc.	Rochester, NY, United States	Exclusive	Worldwide	E-220-2001	Nutritional Supplement to Treat Macular Degeneration
	L-069-2019	2019	LogicBio Therapeutics, Inc.	Lexington, MA, United States	Nonexclusive	Worldwide	E-243-2012	A Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA)
	L-101-2012	2012	Pathology Devices, Inc	Westminster, MD, United States	Nonexclusive	Worldwide	E-002-1998	TUMOR TISSUE MICROARRAYS FOR RAPID MOLECULAR PROFILING
	L-146-2018	2018	Leadiant Biosciences, Inc	Rockville, MD, United States	Exclusive	Worldwide	E-217-2007	Provision Of The Neutral Sugar N-acetyl Nannosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids
	L-186-2016	2016	Galyatech LLC	Diamond Bar, CA, United States	Nonexclusive	Worldwide	E-185-2014	Adeno-associated Viral Gene Therapy As A New Treatment For Niemann-Pick Disease Type C
	L-216-2017	2017	Selecta Biosciences, Inc.	Watertown, MA, United States	Nonexclusive	Worldwide	E-243-2012	A Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA)
	L-216-2018	2018	StrideBio, Inc.	Durham, NC, United States	Nonexclusive	Worldwide	E-100-2017	Novel Codon-optimized And Tagged Human NPC1 Genes And AAV Vectors For The Treatment Of Niemann-Pick Type C1 Deficiency And Related Conditions
NHLBI	L-003-2016	2016	Transmural Systems, LLC	Andover, MA, United States	Exclusive	Worldwide	E-048-2009	Cerclage Locking Device And Delivery System
	L-015-2012	2012	Endoclear LLC	Petoskey, MI, United States	Exclusive	Worldwide	E-061-2004	A Novel System For The Complete Removal Of All Mucus From Within The Tracheal Tube: The Mucus Shaver
	L-029-2012	2012	Koninklijke Philips Electronics N.V.	Eindhoven, , Netherlands	Nonexclusive	Worldwide	E-073-2005	Beta1-insensitive T2 Magnetization Preparation Of MR Imaging At High Field
	L-036-2018	2018	Cook Medical Technologies LLC	Winston Salem, NC, United States	Exclusive	Worldwide	E-027-2013	Transauricular Intrapericardial Tricuspid Annuloplasty (TRAIPTA). A Method And Devices For Non-surgical Treatment For Functional Tricuspid Valve Regurgitation
	L-063-2015	2015	BioMarin Pharmaceutical Inc.	Novato, CA, United States	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-069-2009	2009	Surgi Vision, Inc.	Memphis, TN, United States	Nonexclusive	Other	E-082-2001	Real-Time, Interactive Volumetric Magnetic Resonance Imaging
	L-072-2018	2018	Corvidia Therapeutics, Inc.	Waltham, MA, United States	Exclusive	Worldwide	E-134-2017	ApoC-IIA Mimetic Peptides That Antagonize ApoC-111
	L-074-2012	2012	Vector Biolabs	Philadelphia, PA, United States	Nonexclusive	Worldwide	E-127-1998	AAV5 AND USES THEREOF
	L-074-2016	2016	Transmural Systems, LLC	Andover, MA, United States	Exclusive	Worldwide	E-124-2014	Device For Closure Of Transvascular Or Transcatheter Access Ports
	L-098-2018	2018	T-Cure Bioscience, Inc.	Thousand Oaks, CA, United States	Exclusive	Worldwide	E-120-2016	Transducing T Cells With And HLA All Restricted CT-RCC HERV-E Reactive TCR To Treat Patients With Advanced Clear Cell Kidney Cancer ( CcRCC)
	L-104-2018	2018	LakePharma	Worcester, MA, United States	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-105-2012	2012	GENETHON	, FR, France	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-105-2013	2013	Beat BioTherapeutics Corp.	Seattle, WA, United States	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-107-2007	2007	uniQure B.V.	Amsterdam, , Netherlands	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-120-2012	2012	Sangamo Biosciences	Richmond, CA, United States	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-123-2008	2008	Taconic Farm, Inc.	Germantown, NY, United States	Nonexclusive	Worldwide	E-079-1993	MURINE IL-2RY CDNA AND USES THEREOF
L-124-2017	2017	Generation Bio Co.	Cambridge, MA, United States	Nonexclusive	Worldwide	E-241-2010	Clonal Stable Sf9 Cell Lines Containing Rescuable AAV Vector DNA	
L-143-2007	2007	Hope Pharmaceuticals	Scottsdale, AZ, United States	Exclusive	Worldwide	E-254-2003	Treatment Of Cardiovascular Conditions Using Nitrite Therapy	

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-144-2007	2007	CC Biotech, LLC	Rockville, MD, United States	Exclusive	Worldwide	E-274-1998	Chromatographic Separation of Proteins by Ammonium Sulfate Precipitation
	L-145-2019	2019	Globin Solutions, Inc.	Pittsburgh, PA, United States	Nonexclusive	Worldwide	E-254-2003	Treatment Of Cardiovascular Conditions Using Nitrite Therapy
	L-159-2007	2007	Hope Pharmaceuticals	Scottsdale, AZ, United States	Exclusive	Worldwide	E-254-2003	Treatment Of Cardiovascular Conditions Using Nitrite Therapy
	L-170-2015	2015	BioMarin Pharmaceutical Inc.	Novato, CA, United States	Nonexclusive	Worldwide	E-127-1998	AAV5 AND USES THEREOF
	L-181-2017	2017	Esteve Pharmaceuticals, S.A.	Barcelona, , Spain	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-186-2018	2018	Casebia Therapeutics, LLC	Cambridge, MA, United States	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-195-2020	2020	XCell Science LLC	Novato, CA, United States	Nonexclusive	Worldwide	E-342-2013	Human iPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings
	L-199-2018	2018	Solid Biosciences	Cambridge, MA, United States	Nonexclusive	Worldwide	E-241-2010	Clonal Stable Sf9 Cell Lines Containing Rescueable AAV Vector DNA
	L-209-2017	2017	General Electric Company	Milwaukee, WI, United States	Nonexclusive	Worldwide	E-073-2005	Beta1-insensitive T2 Magnetization Preparation Of MR Imaging At High Field
	L-243-2016	2016	StemCell Technologies Inc.	Vancouver, BC, Canada	Nonexclusive	Worldwide	E-342-2013	Human iPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings
	L-258-2018	2018	Siemens Healthcare GmbH	Berlin, , Germany	Nonexclusive	Worldwide	E-073-2005	Beta1-insensitive T2 Magnetization Preparation Of MR Imaging At High Field
	L-264-2018	2018	Corstem Inc.	Montreal, , Canada	Exclusive	Worldwide	E-219-2018	A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging
	L-275-2018	2018	Hartis-Pharma Sarl	, , Switzerland	Nonexclusive	Worldwide	E-114-2004	Assay System And Composition Of Multi-domain Amphipathic Helical Peptides For The Treatment Of Atherosclerosis.
	L-294-2017	2017	CELiD Biotechnologies, Inc.	Potomac, MD, United States	Nonexclusive	Worldwide	E-241-2010	Clonal Stable Sf9 Cell Lines Containing Rescueable AAV Vector DNA
	L-295-2017	2017	CELiD Biotechnologies, Inc.	Potomac, MD, United States	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-327-2014	2014	Voyager Therapeutics, Inc.	Cambridge, MA, United States	Nonexclusive	Worldwide	E-325-2001	Production of Adeno-Associated Virus in Insect Cells
	L-353-2014	2014	Takara Bio Inc.	Kusatsu, , Japan	Nonexclusive	Worldwide	E-127-1998	AAV5 AND USES THEREOF
	L-095-2013	2013	Bavarian Nordic, Inc.	Mountain View, CA, United States	Exclusive	Worldwide	E-099-1996	AGONIST AND ANTAGONIST PEPTIDES OF CEA
	L-122-2018	2018	Peptron, Inc.	Daejeon, , South Korea	Exclusive	Worldwide	E-249-2016	Exendin-4, GLP-1, GIP And Related Analogs – Optimal Use For Mitigating Neurological Disorders
	L-131-2018	2018	CTS Biopharma LLC	Sunnyvale, CA, United States	Exclusive	US	E-092-2004	Anti-Marinobufagenin Antibody (Clone 3EG) And Uses To Treat Hypertension, Pre-eclampsia, And Eclampsia
	L-160-2007	2007	Life Technologies Corporation	Carlsbad, CA, United States	Nonexclusive	Worldwide	E-272-2005	Invention Of Tools For The Subculture Of Embryonic Stem Cells
	L-166-2016	2016	Elixigen, LLC	Baltimore, MD, United States	Nonexclusive	(blank)	E-088-2007	Zscan4: A Novel Gene Expressed Exclusively In Late 2-cell Embryos And Embryonic Stem Cells
	L-230-2020	2020	PAZ Pharmaceuticals	Washington, DC, United States	Exclusive	Worldwide	E-205-2006	Preparation Of R,R-fenoterol And R,R-fenoterol Analogues And Their Use In Congestive Heart Failure
	L-281-2014	2014	Peptron, Inc.	Daejeon, , South Korea	Exclusive	Worldwide	E-049-2001	Long-Acting Insulinotropic Peptides And Uses Thereof
NIAAA	L-162-2016	2016	Inversago Pharma, Inc	Montreal, , Canada	Exclusive	Worldwide	E-282-2012	Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity



IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-222-2016	2016	TDELTA Limited	, , United Kingdom	Exclusive	Worldwide	E-258-2012	Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation
	L-257-2019	2019	Inversago Pharma, Inc	Montreal, , Canada	Exclusive	Worldwide	E-282-2012	Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity
	L-276-2017	2017	Vital Spark Inc.	New York, NY, United States	Exclusive	Worldwide	E-282-2012	Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity
NIAID	L-001-2015	2015	Merck Sharp & Dohme Corp.	Rahway, NJ, United States	Exclusive	Other	E-171-1988	Vaccine For Dengue Virus
	L-003-2020	2020	Calder Biosciences Inc.	Brooklyn, NY, United States	Nonexclusive	Worldwide	E-081-2013	Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
	L-018-2018	2018	Forte Biosciences Inc.	Torrance, CA, United States	Exclusive	Worldwide	E-099-2016	Use Of Roseomonas Species To Treat Eczematous Skin Disease
	L-021-2010	2010	EXBIO Praha	, , Czech Republic	Nonexclusive	Worldwide	E-255-2000	Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma
	L-028-2019	2019	Ridgeback Biotherapeutics	Miami, FL, United States	Exclusive	Worldwide	E-045-2015	Novel Monoclonal Antibodies To Ebolavirus Glycoprotein
	L-034-2015	2015	Imanis Life Sciences, LLC	Rochester, MN, United States	Nonexclusive	Worldwide	E-552-1982	Recombinant Vaccines for Influenza and Hepatitis B Virus
	L-034-2020	2020	Helocyte, Inc.	New York, NY, United States	Nonexclusive	Worldwide	E-552-1982	Recombinant Vaccines for Influenza and Hepatitis B Virus
	L-037-2006	2006	Apath, LLC	Brooklyn, NY, United States	Nonexclusive	Worldwide	E-100-1999	Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof
	L-046-2017	2017	Medigen Vaccine Biologics Corp	Zhubei , , Taiwan	Nonexclusive	Foreign	E-120-2001	DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
	L-061-2013	2013	BioFactura, Inc.	Rockville, MD, United States	Exclusive	Worldwide	E-145-2004	Chimpanzee Monoclonal Antibodies That Neutralizes Vaccinia Virus (and Possibly Othe Pox Viruses)
	L-063-2006	2006	Sequella, Inc.	Bethesda, MD, United States	Exclusive	Worldwide	E-031-2004	Anti-Tubercular Drug: Compositions And Methods
	L-066-2020	2020	The Native Antigen Company	, , United Kingdom	Nonexclusive	Worldwide	E-004-2009	Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya
	L-068-2005	2005	Fundacao Butantan	Sao Paulo, , Brazil	Exclusive	Foreign	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-069-2010	2010	Beijing Minhai Biotechnology Co., Ltd.	Beijing, , China	Nonexclusive	Worldwide	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-069-2014	2014	BioLegend, Inc.	San Diego, CA, United States	Nonexclusive	Worldwide	E-229-2003	GITR Ligand And Antibodies And Uses Thereof
	L-070-2016	2016	PaxVax, Inc.	Redwood City, CA, United States	Nonexclusive	Worldwide	E-004-2009	Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya
	L-072-2009	2009	BioLegend, Inc.	San Diego, CA, United States	Nonexclusive	Worldwide	E-255-2000	Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma
	L-074-2020	2020	China National Biotec Group Company Limited	Beijing, , China	Nonexclusive	Foreign	E-081-2013	Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
	L-078-2011	2011	CEVA Biomune - Biomune Company	Lenexa, KS, United States	Nonexclusive	Worldwide	E-552-1982	Recombinant Vaccines for Influenza and Hepatitis B Virus
L-080-2006	2006	Panacea Biotech Ltd.	New Delhi , , India	Nonexclusive	Other	E-170-1991	CHIMERIC DENGUE VIRUSES	
L-088-2003	2003	International Medica Foundation	Saint Paul, MN, United States	Exclusive	Worldwide	E-088-2000	Method For Preventing Reactogenicity Associated With Administration Of Immunogenic Live Human-Rhesus Rotavirus Composition	
L-093-2005	2005	Crucell Holland BV	Leiden, , Netherlands	Exclusive	Worldwide	E-241-2001	Development Of A Preventive Vaccine For Filovirus Infection In Primate	
L-101-1985	1985	Pfizer, Inc.	Groton, CT, United States	Nonexclusive	Worldwide	E-552-1982	Process for Using Poxviruses as Vectors for Expression of Foreign Genes	

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-111-2015	2015	Codagenix Inc.	Farmingdale, NY, United States	Exclusive	Worldwide	E-080-2013	Genetically Stable Live Attenuated Vaccine For Respiratory Syncytial Virus (RSV) With Codon Pair Deoptimized And Codon Pair Optimized Elements
	L-116-2018	2018	Katholieke Universiteit Leuven	Leuven, , Belgium	Nonexclusive	Foreign	E-074-2011	A Wild-type Strain Of Genotype 3 Hepatitis E Virus, Its Cell Culture Adapted Progeny, Infectious CDNA Clones Of Each And A Cell Culture System Suitable For Studying Zoonotic Spread Of Hepatitis E
	L-117-2020	2020	Southern Research Institute	Birmingham, AL, United States	Nonexclusive	US	E-074-2011	A Wild-type Strain Of Genotype 3 Hepatitis E Virus, Its Cell Culture Adapted Progeny, Infectious CDNA Clones Of Each And A Cell Culture System Suitable For Studying Zoonotic Spread Of Hepatitis E
	L-118-2009	2009	Sinovac Biotech, Ltd	Beijing, , China	Nonexclusive	Worldwide	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-118-2011	2011	Transwall	West Chester, PA, United States	Nonexclusive	Worldwide	E-102-2010	Sound Attenuation Canopy (SAC); Reduces Noise Transmitted Through The Suspended Ceiling System Present In Most Office Buildings
	L-119-2009	2009	Fundacao Butantan	Sao Paulo, , Brazil	Exclusive	Foreign	E-120-2001	DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
	L-121-2020	2020	Noachis Terra Inc.	Greenwich, CT, United States	Nonexclusive	Worldwide	E-086-2020	Stabilized Wuhan Coronavirus Constructs For Vaccination
	L-130-2005	2005	Biological E. Limited	Hyderabad, , India	Nonexclusive	Foreign	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-135-2017	2017	Emergent Product Development Gaithersburg, Inc.	Gaithersburg, MD, United States	Nonexclusive	Worldwide	E-066-2014	Development Of Modified Hemagglutinin Stem Nanoparticles To Elicit Broad Immune Response To Influenza
	L-142-2007	2007	Transgene S.A.	, , France	Nonexclusive	US	E-552-1982	Recombinant Vaccines for Influenza and Hepatitis B Virus
	L-144-2014	2014	Novartis	Cambridge, MA, United States	Nonexclusive	Worldwide	E-081-2013	Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
	L-149-2015	2015	Serum Institute of India PVT. LTD.	Pune, MH, India	Nonexclusive	Foreign	E-120-2001	DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
	L-150-2020	2020	Medigen Vaccine Biologics Corp	Zhubei , , Taiwan	Nonexclusive	Worldwide	E-234-2016	Stabilized Coronavirus Proteins For Vaccination
	L-154-2006	2006	Merial Limited	Duluth, GA, United States	Nonexclusive	US	E-552-1982	Process for Using Poxviruses as Vectors for Expression of Foreign Genes
	L-155-2018	2018	Icosavax Inc.	Seattle, WA, United States	Nonexclusive	Worldwide	E-081-2013	Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
	L-155-2020	2020	Emergent Product Development Gaithersburg, Inc.	Gaithersburg, MD, United States	Nonexclusive	Worldwide	E-004-2009	Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya
	L-157-2020	2020	Biolegend, Inc.	San Diego, CA, United States	Nonexclusive	Worldwide	E-168-2016	Clearing-enhanced 3D (Ce3D): A Novel Tissue Clearing Method Preserving Cellular Morphology, Reporter Fluorescence, Epitope
	L-158-2020	2020	AbCellera Biologics Inc.	Vancouver, BC, Canada	Exclusive	Worldwide	E-131-2020	Anti-Coronavirus Antibodies And Methods Of Use
	L-162-2015	2015	Merck Sharp & Dohme Research Labs.	, PA, United States	Nonexclusive	Worldwide	E-081-2013	Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-164-2015	2015	Texcell	, , France	Nonexclusive	Worldwide	E-074-2011	A Wild-type Strain Of Genotype 3 Hepatitis E Virus, Its Cell Culture Adapted Progeny, Infectious CDNA Clones Of Each And A Cell Culture System Suitable For Studying Zoonotic Spread Of Hepatitis E
	L-165-2013	2013	SillaJen Biotherapeutics, Inc.	San Francisco, CA, United States	Exclusive	Worldwide	E-552-1982	Recombinant Vaccines for Influenza and Hepatitis B Virus
	L-179-2020	2020	BioNTech AG	Mainz, , Germany	Nonexclusive	Worldwide	E-234-2016	Stabilized Coronavirus Proteins For Vaccination
	L-181-2014	2014	InBios International, Inc.	Seattle, WA, United States	Nonexclusive	Worldwide	E-281-2010	Wuchereria Bancrofti Specific Molecule For The Immunodiagnosis Of Bancroftian Filariasis And For Surveillance Following Successful Control Programs
	L-188-2020	2020	Teraimmune Inc.	Gaithersburg, MD, United States	Exclusive	US	E-279-2011	Stabilization Of Helios-expressing Foxp3+ Human Regulatory T Cells Using Random-sequenced Oligonucleotides
	L-190-2020	2020	Meso Scale Diagnostics, LLC (MSD)	Rockville, MD, United States	Nonexclusive	Worldwide	E-234-2016	Stabilized Coronavirus Proteins For Vaccination
	L-197-2005	2005	Serum Institute of India PVT. LTD.	Pune, MH, India	Nonexclusive	Foreign	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-200-2005	2005	Wuhan Institute of Biological Products, Co., Ltd	Wuhan, , China	Nonexclusive	Other	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-200-2018	2018	Shandong Yidu Biotechnology Co., Ltd.	Shandong , , China	Nonexclusive	Worldwide	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-202-2020	2020	International AIDS Vaccine Initiative, Inc.	New York, NY, United States	Nonexclusive	Worldwide	E-300-2009	Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1 Using Epitope-Specific Glycoprotein Probes To Identify HIV-1 Specific B-Cells
	L-203-2005	2005	Shantha Biotechnics PVT. LTD	Roslyn Heights, NY, United States	Nonexclusive	Worldwide	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-217-2016	2016	Indian Immunologicals Ltd.	Hyderabad, , India	Nonexclusive	Foreign	E-089-2002	Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4
	L-221-2016	2016	Sanofi Pasteur (AVP)	Swiftwater, PA, United States	Exclusive	Worldwide	E-194-1999	Production Of Attenuated Respiratory Syncytial Virus Vaccines Involving Modification Of M2 ORF2
	L-245-1994	1994	BBI-Biotech Research Laboratories, Inc.	Gaithersburg, MD, United States	Nonexclusive	Worldwide	E-471-1985	Cell Line ( 8E5 ) Producing AIDS Viral Antigens Without Producing Infectious Viral Particles.
	L-250-2020	2020	Thermo Fisher Scientific Inc.	Middletown, VA, United States	Nonexclusive	Worldwide	E-234-2016	Stabilized Coronavirus Proteins For Vaccination
	L-251-2020	2020	Thermo Fisher Scientific Inc.	Middletown, VA, United States	Nonexclusive	Worldwide		0
	L-253-2015	2015	Sun Biotech Pte., Ltd	, , Singapore	Nonexclusive	Foreign	E-015-1998	Multivalent Human-Bovine Rotavirus Vaccine
	L-257-2020	2020	GeoVax, Inc.	Atlanta, GA, United States	Nonexclusive	Worldwide	E-552-1982	Recombinant Vaccines for Influenza and Hepatitis B Virus
	L-258-2019	2019	Avidea Technologies	Baltimore, MD, United States	Exclusive	Worldwide	E-191-2018	Improved Methods Of Manufacturing Peptide-Based Vaccines
	L-262-2020	2020	Sanofi Pasteur (AVP)	Swiftwater, PA, United States	Nonexclusive	Worldwide	E-234-2016	Stabilized Coronavirus Proteins For Vaccination
	L-277-2018	2018	Biological E Limited	Hyderabad, , India	Nonexclusive	Foreign	E-217-2004	A Varicella-Zoster Vaccine Mutant Impaired For Latency But Not For Replication
	L-298-2019	2019	GlaxoSmithKline Intellectual Property Limited	, , United Kingdom	Exclusive	Worldwide	E-131-2015	N6, A Novel, Broad, Highly Potent HIV-specific Antibody
	L-303-2019	2019	TaiMed Biologics USA, Inc	Irvine, CA, United States	Nonexclusive	Worldwide	E-051-2012	Further Modifications To HIV Neutralizing Antibodies To Improve Function
	L-333-2014	2014	PATH Vaccine Solutions	Seattle, WA, United States	Nonexclusive	Worldwide	E-281-2010	Wuchereria Bancrofti Specific Molecule For The Immunodiagnosis Of Bancroftian Filariasis And For Surveillance Following Successful Control Programs

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-346-2014	2014	Excell BIO, inc	Saint Paul, MN, United States	Exclusive	Other	E-032-2011	Live-Attenuated Or Inactivated Bivalent Vaccines That Confer Dual Protection Against Rabies And Ebola Viruses
	L-171-2019	2019	Bio X Cell	West Lebanon, NH, United States	Nonexclusive	Worldwide	E-073-2011	Monoclonal Anti-mouse And Anti-human TL1A Antibodies For Diagnostic And Therapeutic Uses
<b>NIBIB</b>	L-004-2019	2019	Sinotau Pharmaceutical Group	Beijing, , China	Exclusive	Worldwide	E-054-2018	Evans Blue Modified Small Molecule Based Prostate-specific Membrane Antigen (PSMA) Radiotherapy
	L-214-2018	2018	Yokogawa Electric Corporation	Tokyo, , Japan	Nonexclusive	Worldwide	E-005-2012	Resolution Doubling With Digital Confocal Microscopy
	L-256-2014	2014	VisiTech International	, , United Kingdom	Nonexclusive	Worldwide	E-005-2012	Resolution Doubling With Digital Confocal Microscopy
	L-276-2018	2018	Molecular Targeting Technologies, Inc	West Chester, PA, United States	Exclusive	Worldwide	E-150-2016	Evans Blue Attachment Enhances Somatostatin Receptor Imaging And Radiotherapy
	L-315-2019	2019	Molecular Targeting Technologies, Inc	West Chester, PA, United States	Exclusive	Worldwide	E-150-2016	Radiotherapy And Imaging Agent Based On Peptide Conjugated To Novel Evans Blue Derivatives With Long Half-life And High Accumulation In Target Tissue
<b>NICHD</b>	L-026-2013	2013	PregLem, SA	Geneva, , Switzerland	Exclusive	Foreign	E-057-2008	Use Of The Selective Progesterone Receptor Modulator CDB-2914 For Treating Uterine Leiomyomata And Stopping Bleeding In Patients Afflicted With Uterine Leiomyomata
	L-059-2010	2010	Cell Signaling Technology, Inc.	Danvers, MA, United States	Nonexclusive	Worldwide	E-010-1998	COMPOSITIONS AND METHODS FOR IDENTIFYING AND TESTING TYROSINE KINASE SUBSTRATES AND THEIR AGONISTS AND ANTAGONISTS
	L-061-2019	2019	Dimension Therapeutics, Inc.	Cambridge, MA, United States	Nonexclusive	Worldwide	E-552-2013	The Enhancer Elements Upstream Of The Human G6PC Minimal Promoter Are Necessary For Efficient Hepatic G6PC Expression
	L-076-2008	2008	Emergent Product Development Gaithersburg, Inc.	Gaithersburg, MD, United States	Nonexclusive	Worldwide	E-023-2002	Methods For Preparing Bacillus Anthracis Protective Antigen For Use In Vaccines (including use of BH445)
	L-080-2009	2009	OriGene Technologies	Rockville, MD, United States	Nonexclusive	Worldwide	E-239-2000	Human Gene Critical To Fertility
	L-080-2020	2020	Computerized Imaging Reference Systems, Inc. (CIRS)	Norfolk, VA, United States	Nonexclusive	Worldwide	E-249-2008	Phantoms For Calibration Of Magnetic Resonance Diffusion Measurements.
	L-167-2017	2017	Cyprium Therapeutics Inc.	New York, NY, United States	Exclusive	Worldwide	E-062-2015	Codon-optimized Reduced-size ATP7A Complementary DNA For Treatment Of Menkes Disease And Related Copper Transport Disorders
	L-172-2019	2019	Genesis Theranostix Ltd.,	Budapest, , Hungary	Nonexclusive	Worldwide	E-348-2013	Development Of A Multimolecular And Multimodular Biomarker Panel For The Early Screening, Molecular Distinction And Clinical Follow-up Of Patients Developing Preeclampsia I HELLP Syndrome And Its Preparation Forpreeclampsia I HELLP Syndrome And Its Preparation For Preclinical Testing
	L-271-2002	2002	BioSource International	Camarillo, CA, United States	Nonexclusive	Worldwide	E-010-1998	COMPOSITIONS AND METHODS FOR IDENTIFYING AND TESTING TYROSINE KINASE SUBSTRATES AND THEIR AGONISTS AND ANTAGONISTS (As Filed)
	L-280-2014	2014	ArcheOptix Biomedical, Inc.	Kingston, , Canada	Exclusive	Worldwide	E-010-2010	Method For The Detection Of A Subdural Hematoma For Use In A Handheld Hematoma Detector And Discriminator.
	L-313-2019	2019	Circumvent Pharm	Pasadena, CA, United States	Exclusive	Worldwide	E-157-2011	Small Molecules (Derivatives Of Hydroxylamine) As Therapeutic Agents For Disorders Caused By Thioesterase Deficiency

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
NIDA	L-070-2003	2003	Brainsway, Inc.	Jerusalem, , Israel	Exclusive	Worldwide	E-223-2000	Coil For Magnetic Stimulation and Methods For Using The Same
	L-220-2017	2017	Braeburn Pharmaceuticals Inc.	Princeton, NJ, United States	Exclusive	Worldwide	E-053-2016	Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders
	L-226-2017	2017	EncepHeal Therapeutics, Inc	Winston Salem, NC, United States	Exclusive	Worldwide	E-073-2013	Phenyl-substituted Thioacetamide And Sulfinylacetamide Modafinil Derivatives As Monamine Transport Inhibitors: Preparation And Use In The Treatment Of CNS Disorders
	L-245-2017	2017	Braeburn Pharmaceuticals Inc.	Princeton, NJ, United States	Exclusive	Worldwide	E-128-2006	4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands With Drug Abuse Therapeutic Potential
	L-250-2018	2018	Hello Bio Ltd.	Bristol , , United Kingdom	Nonexclusive	Worldwide	E-023-2018	New Fluorinated DREADD Actuators And Ligands Suitable For PET Imaging
NIDCD	L-057-2004	2004	Program for Appropriate Tech. in Health	Seattle, WA, United States	Nonexclusive	Foreign	E-301-2003	A Rapid High Efficacy Conjugation Method For Production Of Polysaccharide-Protein Conjugate Vaccines
	L-078-2018	2018	miRecule, Inc.	Rockville, MD, United States	Exclusive	Worldwide	E-043-2016	Functions And Targets Of Therapeutic MicroRNAs To Treat Cancer
NIDCR	L-048-2003	2003	Lee's Pharmaceutical (Hong Kong) Ltd.	, , Hong Kong	Exclusive	Foreign	E-053-2002	Methods and composition For The Promotion of Hair growth Utilizing Act in Binding Peptides
	L-072-2010	2010	Angioblast, Inc.	New York, NY, United States	Exclusive	Worldwide	E-233-2000	Adult Human Dental Pulp Stem Cells In Vitro and In Vivo
	L-076-2008	2008	Emergent Product Development Gaithersburg, Inc.	Gaithersburg, MD, United States	Nonexclusive	Worldwide	E-023-2002	Methods for Preparing Bacillus Anthracis Protective Antigen For Use In Vaccines (including use of BH445)
	L-078-2015	2015	Spark Therapeutics, Inc.	Philadelphia, PA, United States	Nonexclusive	Worldwide	E-308-2001	SCALABLE PURIFICATION OF AAV2, AAV4 OR AAV5 USING ION-EXCHANGE CHROMATOGRAPHY.
	L-115-2020	2020	Kriya Therapeutics, Inc.	Redwood City, CA, United States	Exclusive	Worldwide	E-142-2011	Treatment Of Diabetes By Expression Of A Novel NGF/exendin-4 Fusion Protein From The Salivary Gland Epithelia
	L-248-2015	2015	InBios International, Inc.	Seattle, WA, United States	Nonexclusive	Worldwide	E-036-2010	Simple, Quantitative, And Highly Sensitive Antibody Detection For Lyme Disease
	L-263-2018	2018	MeiraGTX, LLC	New York, NY, United States	Exclusive	(blank)	E-139-2011	Treatment Of Autoimmune Xerostomia By AAV2 Mediated Gene Transfer Of Aquaporin 1 To Salivary Gland Epithelia
	L-343-2001	2001	List Biological Laboratories, Inc.	Campbell, CA, United States	Nonexclusive	Worldwide	E-159-1999	A HIGHLY EFFICACY, HIGH YIELD PERTUSSIS VACCINE AND METHOD FOR MAKING SAME.
NIDDK	L-008-2020	2020	Bio-Techne Ltd	Abingdon, , United Kingdom	Nonexclusive	Worldwide	E-022-2019	Nucleoside Agonists Of Adenosine Receptors
	L-075-2017	2017	Biolntervene Inc.	St. Louis, MO, United States	Exclusive	Worldwide	E-140-2008	Design Of (N)-Methanocarpa Adenosine 5'Uronamides As Species-Independent A3 Receptor-Selective Agonists
	L-082-2013	2013	Cornovus Pharmaceuticals, Inc.	Farmington, CT, United States	Exclusive	Worldwide	E-176-1999	Methanocarpa Analogues of Purine And Pyrimidine Nucleosides And Nucleotides as Ligands For P1 And P2 Receptors.
	L-097-2020	2020	Astrocyte Pharmaceuticals, Inc	Cambridge, MA, United States	Exclusive	Worldwide	E-138-2017	Compounds And Methods For Treating Brain Injury
	L-149-2017	2017	Aegerion Pharmaceuticals, Inc.	Cambridge, MA, United States	Exclusive	Worldwide	E-064-2004	The Use Of Leptin For Treating Human Lipotrophy
	L-151-2012	2012	DecisionQ Corporation	Arlington, VA, United States	Exclusive	Worldwide	E-219-2011	Model For Providing A Patient-specific Diagnosis Of Disease Using Clinical Dataprobability Of Transplant Glomerulopathy

IC	License No.	FY	Name	Address	Exclusivity	Territory	Tech. No.	Tech. Title
	L-172-2008	2008	Johns Hopkins University (JHU)	Baltimore, MD, United States	Nonexclusive	Worldwide	E-148-1992	S9 And C38 Cell Lines Which Are CFBE IB3-1 (IB3 Is A Human Bronchial Epithelial Cell Line) Transfected Cell Lines
	L-265-2002	2002	Tocris Cookson Ltd.	Bristol, , United Kingdom	Nonexclusive	Worldwide	E-176-1999	Methanocarba Analogues of Purine And Pyrimidine Nucleosides And Nucleotides as Ligands For P1 And P2 Receptors.
	L-324-2017	2017	FM Therapeutics Co., Ltd.	Seoul, , South Korea	Exclusive	Worldwide	E-109-2006	Novel, Potent And Selective A3 Adenosine Receptor Antagonists
	L-339-2017	2017	AltraTech Ltd	Shannon, , Ireland	Nonexclusive	Worldwide	E-260-2012	Cyclopentane-Peptide Nucleic Acids For Qualitative And Quantitative Detection Of Nucleic Acids
<b>NIEHS</b>	L-065-2001	2001	Millipore Sigma	Billerica, MA, United States	Nonexclusive	Worldwide	E-170-2000	A Non-Steroidal Anti-Inflammatory Drug Related Gene (NAG-1) And Secreted Protein That Has Anti-Tumorigenic Properties
<b>NIMH</b>	L-064-2010	2010	Angimmune LLC	Bethesda, MD, United States	Exclusive	Worldwide	E-012-1991	IMMUNOTOXIN WITH IN-VIVO T CELL SUPPRESSANT ACTIVITY
	L-185-2020	2020	Defender Pharmaceuticals, Inc.	Tampa, FL, United States	Exclusive	Worldwide	E-175-2004	Scopolamine For The Treatment Of Depression And Anxiety
	L-302-2014	2014	KannaLife Sciences, Inc.	West Hills, NY, United States	Nonexclusive	(blank)	E-287-1997	CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTANTS
	L-313-2014	2014	Angimmune LLC	Bethesda, MD, United States	Exclusive	Worldwide	E-044-1997	NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE
	L-327-2002	2002	Shimadzu Corporation	Columbia, MD, United States	Exclusive	Worldwide	E-088-2002	Multi-dimensional Liquid Chromatography Separation System
<b>NINDS</b>	L-002-2019	2019	Geneuro SA	Lausanne, , Switzerland	Exclusive	Worldwide	E-088-2018	Anti-HERV-K Envelope Antibody And Uses Thereof
	L-024-2006	2006	NeoPharm, Inc.	Lake Bluff, IL, United States	Nonexclusive	Worldwide	E-173-1992	CONVECTION-ENHANCED DRUG DELIVERY
	L-050-2011	2011	Passy-Muir, Inc.	Irvine, CA, United States	Exclusive	Worldwide	E-251-2005	Enhance Recovery Of Voluntary Swallowing Using Patient Control Of Vibro-tactile Stimulation To The Neck In Persons With Dysphagia Resulting From A Neurological Diseases Or Disorders
	L-070-2003	2003	Brainsway, Inc.	Jerusalem, , Israel	Exclusive	Worldwide	E-223-2000	Coil For Magnetic Stimulation and Methods For Using The Same
	L-092-2017	2017	Cogentis Therapeutics, Inc.	Baltimore, MD, United States	Exclusive	Worldwide	E-144-2010	Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide
	L-170-2017	2017	AestasRx Inc.	Lewisville, NC, United States	Exclusive	Worldwide	E-144-2010	Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide
	L-213-1994	1994	Panlabs, Inc.	Bothell, WA, United States	Nonexclusive	Worldwide	E-230-1989	CDNA ENCODING THE LONG ISOFORM OF THE D2 DOPAMINE RECEPTOR.
	L-217-2014	2014	Medicenna Therapeutics, Inc.	Toronto, , Canada	Exclusive	Worldwide	E-202-2002	METHOD FOR CONVECTION ENHANCED DELIVERY OF THERAPEUTIC AGENTS
	L-229-2016	2016	Great Lakes Neuroscience Inc.	Grayslake, IL, United States	Exclusive	Worldwide	E-144-2010	Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide
<b>NINR</b>	L-079-2017	2017	VuEssence, Inc.	Odessa, FL, United States	Co-Exclusive	Worldwide	E-023-2010	A Gene Expression Biomarker Panel For Diagnosis Of Acute Ischemic Stroke
	L-132-2017	2017	CereDx Inc.	Morgantown, WV, United States	Co-Exclusive	Worldwide	E-023-2010	A Gene Expression Biomarker Panel For Diagnosis Of Acute Ischemic Stroke